New antibody treatment shows promise for tough kidney disease
Disease control
Completed
This study tested a new drug, MIL62, in 94 adults with primary membranous nephropathy, a serious kidney condition. The goal was to see if MIL62 is safe and can help reduce protein in the urine better than the standard drug cyclosporine. Participants received either MIL62 or cyclo…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC